Use of rosiglitazone before and after vascular injury in hypercholesterolemic rabbits: Assessment of neointimal formation

Thrombosis Journal

Volumn 6, Issue , 2008, Pages

  Alessi, Alexandre ^a   Neto, Olímpio Ribeiro França ^a   Brofman, Paulo Roberto Slud ^a   Prim, Camila ^a   Noronha, Lucia ^a   Silva, Ruy Fernando Kuenzer Caetano ^a   Baroncini, Liza Andréa Villela ^a   Précoma, Dalton Bertolim ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTERY INJURY; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; BALLOON CATHETER; CONTROLLED STUDY; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; ILIAC ARTERY; LIPID DIET; MALE; MORPHOMETRICS; NONHUMAN; RABBIT;

EID: 52449121465     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-6-12     Document Type: Article

References (38)

1. Phillips JW Barringhaus KG Sanders JM Yang Z Chen M Hesselbacher S Czarnik AC Ley K Nadler J Sarembock IJ Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes Circulation 2003, 108:1994-1999. 10.1161/ 01.CIR.0000092886.52404.50 14517165
2. Seki N Bujo H Jiang M Shibasaki M Takahashi K Hashimoto N Saito Y A potent activator of PPARα and γ reduces the vascular cell recruitment and inhibits the intimal thickning in hypercholesterolemic rabbits Atherosclerosis 2005, 178:1-7. 10.1016/ j.atherosclerosis.2004.08.015 15585194
3. Calkin AC Forbes JM Smith CM Lassila M Cooper ME Jandeleit-Dahm KA Allen TJ Rosiglitasone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects Arterioscler Thromb Vasc Biol 2005, 25:1903-1909. 10.1161/01.ATV.0000177813.99577.6b 16020748
4. Blaschke F Spanheimer R Khan M Law RE Vascular effects of TZDs: New implications Vascular Pharmacology 2006, 45:3-18. 10.1016/ j.vph.2005.11.009 16740417
5. Badimon JJ Fernadez-Ortiz A Meyer B Mailhac A Fallon JT Falk E Badimon L Chesebro JH Fuster V Different response to balloon angioplasty of carotid and coronary arteries: Effects on acute platelet deposition and intimal thickening Atherosclerosis 1998, 140:307-314. 10.1016/ S0021-9150(98)00134-8 9862273
6. Wilenski RL March KL Gradus-Pizlo I Sandusky G Fineberg N Hathway DR Vascular injury, repair and restenosis after percutaneos transluminal angioplasty in the atherosclerotic rabbit Circulation 1995, 92:2995-3005. 7586270
7. Zhu BQ Smith DL Sievers RE Isemberg WM Parmley WW Inhibition of atherosclerosis by fish oil in cholesterol-fed rabbits J AM Coll Cardiol 1988, 12:1073-1078. 3417980
8. Ross R The patogenesis of atherosclerosis: A perspective for 1990s Nature 1993, 362:801-809. 10.1038/362801a0 8479518
9. Hsueh WA Law RE PPARγ and atherosclerosis. Effects on cell growth and movement Arterioscler Thromb Vasc Biol 2001, 21:1891-1895. 10.1161/ hq1201.100261 11742860
10. Rosmarakis ES Falagas ME Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: A meta-analysis of randomized controlled trials Am Heart J 2007, 154:144-50. 10.1016/ j.ahj.2007.04.005 17584567
11. Bhatt DL Chew DP Grines C Mukherjee D Leesar M Gilchrist IC Corbelli JC Blankenship JC Eres A Steinhubl S Tan WA Resar JR AlMahameed A Abdel-Latif A Tang HW Brennan D McErlean E Hazen SL Topol EJ Peroxisome proliferator-activated receptor γ agonists for the prevention of adverse events following percutaneous coronary revascularization-results of the PPAR study Am Heart J 2007, 154:137-43. 10.1016/j.ahj.2007.03.029 17584566
12. Riche DM Valderrama R Henyan NN Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention Diabetes Care 2007, 30:384-388. 10.2337/dc06-1854 17259517
13. Igarashi M Takeda Y Ishibashi N Takahashi K Mori S Tominaga M Saito Y Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization Horm Metab Res 1997, 29(9):444-449. 9370113
14. Taskiran D Taskiran E Yercan H Kutay FZ Quantification of total collagen in rabbit tendon by the Sirius red method Tr J of Medical Scienses 1999, 29:7-9.
15. Virmani R Kolodgie FD Burke AP Farb A Schwartz SM Lessons from sudden coronary death. A comprehensive morphological classification scheme for atherosclerotic lesions Arterioscler Thromb Vasc Bio 2000, 20:1262-1275.
16. Wang ZH Luo F Liu XM Effect of PPARgamma agonist rosiglitazone on regression of the atherosclerotic plaques in rabbits Yao Xue Xue Bao 2005, 40(11):1051-3. 16499094
17. Heckencamp J Gawenda M Brunkwall J Vascular restenosis: Basic science and clinical implications J Cardiovasc Surg (Torino) 2002, 43(3):349-357. 12055567
18. Schomig A Kastrati A Wessely R Prevention of restenosis by systemic drug therapy: Back to the future Circulation 2005, 112:2759-2761. 10.1161/ CIRCULATIONAHA.105.583484 16267248
19. Schwartz RS Henry TD Pathophysiology of Coronary Artery Restenosis Rev Cardiovasc Med 2002, 3(Suppl 5):S4-9. 12478229
20. Takagi T Akasaka T Yamauchi M Troglitazone reduces neointimal tissue proliferation after coronary stent implantantion in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study J Am Coll Cardiol 2000, 36:1529-1535. 10.1016/ S0735-1097(00)00895-0 11079654
21. Osborne JA Lento PH Siegfried MR Stahl GL Fusman B Lefer AM Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment J Clin Invest 1989, 83:465-473. 303702 2913050 10.1172/JCI113905
22. Sun YP Lu NC Parmililitrosey WW Hollenbeck CB Effects of cholesterol diets on vascular function and atherogenesis in rabbits Diets, Vascular Finction, and Atherogenesis 2000, 224:166-171.
23. Golledge J Mangan S Clancy P Effects of peroxisome proliferator-activated receptor ligands in modulating tissue-factor and tissue-factor pathway inhibitor in acutely symptomatic carotid atheromas Stroke 2007, 38:1501-1507. 10.1161/STROKEAHA.106.474791 17363721
24. Liu HR Tao L Gao E Lopez BL Christopher TA Willette RN Ohlstein EH Yue TL Ma XL Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion Cardiovascular research 2004, 62:135-144. 10.1016/j.cardiores.2003.12.027 15023560
25. Chawla A Barak Y Nagy L Liao D Tontonoz P Evans RM PPAR gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation Nat Med 2001, 7:48-52. 10.1038/83336 11135615
26. Choi D Kim SK Choi SH Ko YG Ahn CW Jang Y Lim SK Lee HC Cha BS Preventive effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes Diabetes Care 2004, 27:2654-2660. 10.2337/diacare.27.11.2654 15505001
27. Collins AR Meehan WP Kintscher U Jackson S Wakino S Noh G Palinski W Hsueh WA Law RE Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and non-diabetic low density lipoprotein receptor-deficient mice Atheroscler Thromb Vasc Biol 2001, 21:365-371.
28. Dormandy JA for the PROactive investigators et al. Secundary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomized controlled trial Lancet 2005, 366:279-1289. 10.1016/S0140-6736(05)67528-9 16044531
29. Hodis HN Mack WJ Zheng L Li Y Torres M Sevilla D Stewart Y Hollen B Garcia K Alaupovic P Buchanan TA Effect of peroxisome proliferator-activated receptor γ agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes Diabetes Care 2006, 29:1545-1553. 10.2337/dc05-2462 16801577
30. Hsueh WA Jackson S Law RE Control of vascular cell proliferation and migration by PPAR gamma Diabetes Care 2001, 24:392-397. 10.2337/ diacare.24.2.392 11213897
31. França Neto OR Précoma DB Alessi A Prim C Silva RFKC Noronha L Baroncini LAV Effects of rosiglitazone on contralateral iliac artery after vascular injury in hypercholesterolemic rabbits Thromb J 2008, 6:4. 18485218 2396603 10.1186/1477-9560-6-4
32. Nissen SE Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 2007, 356:2457-2471. 10.1056/NEJMoa072761 17517853
33. Singh S Loke YH Furberg CD Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis JAMA 2007, 298:1216-8. 10.1001/ jama.298.10.1216 17848659
34. Lipscombe LL Gomes T Lévesque LE Hux JE Juurlink DN Alter DA Thiazolidinediones and cardiovascular outcomes in older patients with diabetes JAMA 2007, 298(10):1189-95. 10.1001/jama.298.10.1189 17848653
35. Patel CB De Lemos JA Wyne KL Mcguire DK Thiazolidinediones and risk for atherosclerosis: Pleitropic effects of PPARγ agonism Diabetes Vasc Dis Res 2006, 3:65-71. 10.3132/dvdr.2006.016
36. Home PD Pocock SJ Beckk-Nielsen H Gomis R Hanefeld M Joses NP Komajda M McMurray JJV for the Record Study Group Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis N Engl J Med 2007, 357:28-38. 10.1056/NEJMoa073394 17551159
37. Nissen SE Nicholls SJ Wolski K Nesto R Kupfer S Perez A Jure H De Larochellière R Staniloae CS Mavromatis K Saw J Hu B Lincoff AM Tuzcu EM Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. The PERISCOPE randomized controlled trial JAMA 2008, 299:1561-1573. 10.1001/ jama.299.13.1561 18378631
38. Barbier O Torra IP Duguay Y Blanquart C Fruchart JC Glineur C Staels B Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis Arterioscler Thromb Vasc Bio 2002, 22:717-726. 10.1161/01.ATV.0000015598.86369.04